ABSTRACT

The International Diabetes Federation (IDF) defines the metabolic syndrome (MS) as the co-occurrence of any three of the five following abnormalities : abdominal obesity (waist circumference > 94 cm in men and > 80 in women), dyslipidemia (triglyceridemia > 1.5 mmol/l, HDL cholesterol < 0.4 g/l in men and < 0.5 g/l in women), blood pressure (BP) > 130/85 and/or medical treatment, and fasting glycemia > 5.55 mmol/l and/or medical treatment [1]. MS is associated with an increased risk of cardiovascular diseases [2] and prevalence of type 2 diabetes [3]. In developed countries, its increasing prevalence is mainly linked to obesity and age [4].